Prior authorization for biologic disease-modifying antirheumatic drugs: a description of US Medicaid programs.
about
Practice characteristics and prior authorization costs: secondary analysis of data collected by SALT-Net in 9 central New York primary care practices.Factors associated with initial or subsequent choice of biologic disease-modifying antirheumatic drugs for treatment of rheumatoid arthritis.Cost of tumor necrosis factor blockers per patient with rheumatoid arthritis in a multistate Medicaid populationEvaluating the impact of a novel restricted reimbursement policy for quinolone antibiotics: a time series analysisEfficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study.Biosimilars for the management of rheumatoid arthritis: economic considerations.
P2860
Prior authorization for biologic disease-modifying antirheumatic drugs: a description of US Medicaid programs.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Prior authorization for biolog ...... ption of US Medicaid programs.
@en
Prior authorization for biolog ...... ption of US Medicaid programs.
@nl
type
label
Prior authorization for biolog ...... ption of US Medicaid programs.
@en
Prior authorization for biolog ...... ption of US Medicaid programs.
@nl
prefLabel
Prior authorization for biolog ...... ption of US Medicaid programs.
@en
Prior authorization for biolog ...... ption of US Medicaid programs.
@nl
P2093
P2860
P356
P1476
Prior authorization for biolog ...... ption of US Medicaid programs.
@en
P2093
Amber D Servi
Daniel H Solomon
Jennifer M Polinski
Jessica Agnew-Blais
Liljana Kaci
Michael A Fischer
P2860
P304
P356
10.1002/ART.24191
P577
2008-11-01T00:00:00Z